Pancreatic secretion of benzylpyrimidines. Experimental studies in dogs.
The high mortality of septicaemic complications in pancreatic diseases requires the prophylactic use of suitable antimicrobial agents. Thus, the pancreatic distribution of benzylpyrimidines has been studied in dogs. After injection of 5 mg/kg followed by constant infusion of 0.5 mg/kg/h, maximum concentrations of 3.88 +/- 1.46 micrograms/ml (metioprim, MTP), 6.07 +/- 4.95 micrograms/ml (trimethoprim, TMP) and 7.78 +/- 1.84 micrograms/ml (tetroxoprim, TXP) were reached in canine pancreatic secretion. With respect to plasma, the drugs show 2.72- (MTP), 3.57- (TMP) and 4.18fold (TXP) concentrations in pancreatic secretion as can be shown by calculation of the AUC-ratios.
D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D005260:Female; D006863:Hydrogen-Ion Concentration; D008297:Male; D010179:Pancreas / Q000378:metabolism*; D011743:Pyrimidines / Q000378:metabolism; D013997:Time Factors; D014295:Trimethoprim / Q000031:analogs & derivatives* / Q000378:metabolism
D000890:Anti-Infective Agents; D011743:Pyrimidines; C023507:tetroxoprim; D014295:Trimethoprim; C036263:metioprim